ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...
Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...
Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...
In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...
An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...
Chelsea Cirruzzo is a Washington correspondent at STAT, where she covers HHS. You can reach Chelsea on Signal at chelseacirruzzo.42. WASHINGTON — House appropriators have snubbed Health and Human ...
The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...
The Manila Times on MSN
Bayer sues COVID vaccine makers over mRNA technology
Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ...
Immunomic Therapeutics, Inc. ("ITI"), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback